Successful Use of Aliskiren in a Case of IgA- Mesangial Glomerulonephritis Unresponsive to Conventional Therapies

2019 ◽  
Vol 14 (1) ◽  
pp. 72-76 ◽  
Author(s):  
Mariadelina Simeoni ◽  
Ramona Nicotera ◽  
Elena Pelagi ◽  
Emanuela Libri ◽  
Nicolino Comi ◽  
...  
Keyword(s):  
Adverse Event ◽  
Case Report ◽  
Therapeutic Option ◽  
Potential Usefulness ◽  
Iga Glomerulonephritis ◽  
Renin Inhibition

Introduction: The early suspension of Altitude trial in recent years has induced most nephrologists and cardiologists to abandon Aliskiren use. Consequently, the potential usefulness of the direct renin inhibition in IgA glomerulonephritis remained an under-investigated therapeutic option. </P><P> Case Report: We report the case of a 53 years old IgA GMN patient unresponsive to all conventional anti-angiotensin-2 agents, steroids and immunosuppressants, in which the administration of Aliskiren permitted to achieve and maintain a complete proteinuria remission in the absence of any adverse event. Conclusion: Aliskiren might represent a valid and safe therapeutic option in IgA GMN, although further investigations would be needed to confirm this conclusion.

scholarly journals Extraocular muscle repositioning as the last therapeutic option for a patient with a severe course of Graves’ Ophthalmopathy: a case report

2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Andrea Rau ◽  
Matthias Klopfer ◽  
Niklas Rommel ◽  
Mechthild Rau-Fornefeld ◽  
Andreas Kolk
Keyword(s):  
Case Report ◽  
Extraocular Muscle ◽  
Therapeutic Option ◽  
Graves Ophthalmopathy

scholarly journals Case Report. Extracorporeal Membrane Oxygenation in Nivolumab Associated Pneumonitis

2017 ◽  
Vol 3 (2) ◽  
pp. 84-88
Author(s):  
Thomas-Michael Schneider ◽  
Friederike Klenner ◽  
Franz Brettner
Keyword(s):  
Case Report ◽  
Extracorporeal Membrane Oxygenation ◽  
Therapeutic Option ◽  
High Dose ◽  
Great Success ◽  
Case Presentation ◽  
Computed Tomographic ◽  
Rehabilitation Hospital ◽  
Membrane Oxygenation ◽  
History Of

Abstract Background: Newly approved immunotherapeutic agents, like CTLA-4 inhibitors and antibodies against PD-1, are a promising therapeutic option in cancer therapy. Case presentation: A 74-year-old man, with a history of advanced stage melanoma and treatment with ipilimumab, pembrolizumab and nivolumab, was admitted to the hospital due to respiratory failure with hypoxemia and dyspnoea. He rapidly developed severe acute respiratory distress syndrome (ARDS), which required treatment in the intensive care unit which included mechanical ventilation and extracorporeal membrane oxygenation (ECMO). Computed tomographic imaging (CT) showed signs of a pneumonitis, with an ARDS pattern related to the use of PD-1 antibodies. Treating the patient with high-dose immunosuppressive steroids led to an overall improvement. He was transferred to a rehabilitation hospital and subsequently to his home. Discussion and conclusion: This is a unique case report of a patient suffering a grade 4 adverse event under nivolumab who survived having been treated with ECMO. It highlights the possibility of associated adverse reactions as well as the use of ECMO in palliative care patients. ECMO can be of great success even in patients with malignancies, but careful decision making should be done on a case by case basis.

scholarly journals Management of tubal ectopic pregnancy with methotrexate in the setting of symptomatic Coronavirus disease 2019 (COVID-19): A case report

2021 ◽  
Vol 13 (3) ◽  
pp. 277-281
Author(s):  
N.M. Millan ◽  
J Morano ◽  
L Florez ◽  
J Carugno ◽  
C.A. Medina
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Supportive Care ◽  
Medical Management ◽  
Patient Management ◽  
Therapeutic Option ◽  
Careful Consideration ◽  
Management Options ◽  
Tubal Ectopic Pregnancy ◽  
Ectopic Pregnancies

Background: Coronavirus Disease 2019 (COVID-19) represents a complex therapeutic challenge. As the pandemic progresses, patients are presenting with ectopic pregnancies (EPs) and symptomatic COVID-19. Objective: We present the management of a patient with multiple medical comorbidities and tubal EP in the setting of severe symptomatic COVID-19 infection where all management options were precluded. Methods: Case report with literature review of management of tubal EP in the setting of severe symptomatic COVID-19 infection. Result: After careful consideration of options, the patient underwent successful medical management with methotrexate while receiving supportive care for COVID-19. Conclusions: Methotrexate proved to be the safest therapeutic option in this patient. Management of patients with severe COVID-19 and gynaecologic emergencies should be individualised and carefully reviewed with evolving knowledge of COVID-19.

scholarly journals SP155TEMPORALLY CARDIOVASCULAR ADVERSE EVENT DURING RITUXIMAB INFUSION: A CASE REPORT

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii429-iii429 ◽  
Author(s):  
Laura Rivoli ◽  
Nicolino Comi ◽  
Elena Pelagi ◽  
Giuseppe Coppolino ◽  
Giorgio Fuiano
Keyword(s):  
Adverse Event ◽  
Case Report ◽  
Cardiovascular Adverse Event

scholarly journals Optimizing Secukinumab Treatment in Psoriasis with Concomitant Methotrexate Administration: Minireview and A Case Report

2019 ◽  
Vol 11 (1) ◽  
pp. 17-22 ◽  
Author(s):  
Dimitra Kostaki ◽  
Emilia Aquila ◽  
Laura Macaluso ◽  
Carlo Mattozzi ◽  
Antonio Giovanni  Richetta
Keyword(s):  
Quality Of Life ◽  
Adverse Event ◽  
Case Report ◽  
Biologic Agents ◽  
Drug Side Effects ◽  
Biologic Drugs ◽  
Treatment Regimens ◽  
Systemic Therapies ◽  
Event Occurrence

The introduction of biologic drugs for the treatment of moderate-to-severe psoriasis resulted in a significant improvement in patients’ health. Moreover, treatment regimens in psoriatic patients should be tailored to meet specific needs based on disease severity, impact on quality of life, response to previous therapies and presence of comorbidities. Combination therapy of biologic agents with conventional systemic drugs has been proposed to optimize psoriasis treatment outcomes in unresponsive or partial responsive severe psoriatic patients. We report the case of a patient with a long-standing recalcitrant plaque psoriasis and psoriatic arthritis who was administered secukinumab combined with methotrexate. The patient had previously been treated with several topical and systemic therapies associated with loss of efficacy or adverse event occurrence. Approximately 24 weeks after starting the combined regimen, significant clearance of psoriasis and reduction of arthritis ensued, with no drug side effects.

Sign in / Sign up

Export Citation Format

Share Document